Hepatitis C
13.05.2022 | laboratory study
GMOP-IFN-Alpha-2b: Stable De-Immunized Interferon
Non-immunogenic interferon with a long elimination period can help in the treatment of chronic hepatitis and other viral diseases
03.05.2020 | expert opinion
Is large-scale screening of the population for the hepatitis C virus justified?
Most Hep C virus hosts never show symptoms of the disease. For them, the side effects of treatment may exceed the clinical benefit
03.05.2020 | review
New treatment for hepatitis C: faster effect, better survival rate
While scientists argue what is more harmful: the disease itself or the side effects of drugs, the hepatitis C community in the United States shares good news. Modern hepatitis C therapy in 97% of cases passes without serious health consequences within 2 years